Copertina

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	John David Chetwood, Nik Sheng Ding
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply
di: Rocío Ferreiro‐Iglesias, et al.
Pubblicazione: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Letter: Steroid Tapering—Is Shorter Duration Better?
di: Juntao Lu, et al.
Pubblicazione: (2026)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
di: Richard Pollok
Pubblicazione: (2025)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
di: Daniel Tassone, et al.
Pubblicazione: (2024)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
di: Nicholas Clark, et al.
Pubblicazione: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
di: Rónán O'Connor, et al.
Pubblicazione: (2026)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
di: Sarah Melton, et al.
Pubblicazione: (2025)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
di: Ankit Kumar, et al.
Pubblicazione: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
di: Ganesh Bhat, et al.
Pubblicazione: (2026)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
di: Merle Claßen, et al.
Pubblicazione: (2024)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
di: Amol N. Patil, et al.
Pubblicazione: (2026)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
di: Hariti Saluja, et al.
Pubblicazione: (2026)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
di: Brian C. Weiner
Pubblicazione: (2025)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Editorial: Striving for Equitable Care in Ulcerative Colitis
di: Edward L. Barnes
Pubblicazione: (2025)

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma
di: Enrico N. De Toni, et al.
Pubblicazione: (2024)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
di: Iris Barth, et al.
Pubblicazione: (2024)

Meta‐Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis
di: Matthew K. W. Chu, et al.
Pubblicazione: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Antoine Meyer, et al.
Pubblicazione: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
di: Johan D. Söderholm
Pubblicazione: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Should ulcerative colitis be monitored more or less invasively?
di: David Laharie
Pubblicazione: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
di: Mark A. Ainsworth, et al.
Pubblicazione: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
di: Anish J. Kuriakose Kuzhiyanjal, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
di: Jing Li, et al.
Pubblicazione: (2024)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
di: Mathilde Osty, et al.
Pubblicazione: (2025)

Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study
di: Tom van Gils, et al.
Pubblicazione: (2024)

The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
di: Laurie‐Rose Dubé, et al.
Pubblicazione: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
di: Ahmed B. Bayoumy, et al.
Pubblicazione: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
di: Arshdeep Singh, et al.
Pubblicazione: (2025)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
di: Shintaro Akiyama
Pubblicazione: (2025)

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020
di: J. Couch, et al.
Pubblicazione: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
di: Shinichiro Shinzaki, et al.
Pubblicazione: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
di: Aakash Desai, et al.
Pubblicazione: (2025)

Review: Human Intestinal Barrier—Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration
di: Michael Camilleri
Pubblicazione: (2025)